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The inﬂammatory responses in sepsis and hemorrhage remain a major cause of death. Clinically, it is generally accepted that
shock in sepsis or hemorrhage diﬀers in its mechanisms. However, the recognition of inﬂammatory cytokines as a common
lethal pathway has become consent. Proinﬂammatory cytokines such as tumor necrosis factor (TNF) or high-mobility group
box1 (HMGB1) are fanatically released and cause lethal multiorgan dysfunction. Inhibition of these cytokines can prevent the
inﬂammatory responses and organ damage. In seeking potential anti-inﬂammatory strategies, we reported that ethyl pyruvate and
alpha7 nicotinic acetylcholine receptor (alpha7nAChR) agonists eﬀectively restrained cytokine production to provide therapeutic
beneﬁts in both experimental sepsis and hemorrhage. Here, we review the inﬂammatory responses and the anti-inﬂammatory
strategies in experimental models of sepsis and hemorrhage, as they may have a consistent inﬂammatory pathway in spite of their
diﬀerent pathophysiological processes.
1.Introduction
Bacterial toxins can cause respiratory and cardiac failure
or even death within the ﬁrst 24–48 hours after infection.
The body’s responses to foreign invasion can in some cases,
depending on the amount of insult, initiate an immunologic
protection to eliminate the insult. A fanatical production of
proinﬂammatory cytokines such as TNF produced during
endotoxemiamaycauseorganinjuryoreventualdeath[1,2],
even though TNF may be required in healing the damaged
tissues caused by infection or injury in the early stage or
mild inﬂammatory response. In mounting reports and the
experiments of sepsis and other stresses such as trauma and
acute hemorrhage carried out by us recently, the deleterious
inﬂammatory responses were obviously evidenced to present
a variety of signs and symptoms of cardiovascular collapse
and multiorgan dysfunctions, which can be prevented by
inhibition TNF [3, 4]. In seeking anti-inﬂammatory sup-
plements to restrain TNF production, we found the ethyl
pyruvate and alpha7nAChR agonists eﬀectively inhibit TNF
production in sepsis and hemorrhage [5, 6].
In addition to TNF, high mobility group B protein-1
(HMGB1) is a characteristic “late” factor contributing to
endothelial leakage, vascular collapse, acute lung injury,
heart failure, or even sudden cardiac death. HMGB1 is a
constitutive intracellular protein that is released into the
extracellular milieu from damaging cells in response to
the inﬂammation during hemorrhage or sepsis. Following
acute inﬂammation, the immune system is able to recognize
the HMGB1 as a hazard molecule. In looking for anti-
inﬂammatory therapeutic strategies, we have also found
ethyl pyruvate and alpha7nAcChR agonist choline posses a
potential inhibition of HMGB1 leading to improvement of
animal survival after hemorrhage or sepsis [5–7]. Here, we
review the new insights on the mentions.
2. SystemicInﬂammation inSepsis
Sepsis is one of the most common causes of death in hospi-
talized patients accounting for 9.3% of overall deaths in the
United States annually. Sepsis aﬀects over 18 million people
worldwide and it is expected 1% increase in incidence per
year [1, 2]. Sepsis is characterized by bacterial infection with
atleastclinicalmanifestationsofthefollowing:abnormalities
of body temperature (hypothermia or hyperthermia), heart
rate (tachycardia), respiratory rate (tachypnea), and white2 Mediators of Inﬂammation
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Figure 1: Nicotinic anti-inﬂammatory pathways. The inﬂammatory response to the infection, hemorrhage, or tissue trauma is mediated
throughthepathwaysofcytokineHMGB1,TNF,andinterleukinswhicharereleasedfromimmunizedcellsoflymphsystemincludingspleen
tissue. Such immune pathway can be modulated by vagus nerve via its acetylcholine transmitter through either muscarinic or nicotinic
receptor. A nicotinic acetylcholine receptor (α7nAChR) agonist, such as nicotine, or transmitter released from vagus nerve stimulation,
can inhibit the inﬂammation through restraining the production of proinﬂammatory cytokines from lymphocyte macrophage line. As
cholinergic selective, nicotine is more eﬃcient than acetylcholine in anti-inﬂammatory response through α7nAChR-dependent mechanism.
blood cell count (leukocytopenia or leukocytosis). Two
clinical syndromes have been associated with sepsis. “Septic
shock” is highly lethal syndrome of cardiovascular shock
that kills within 24–48 hours since onset. Shock is invariably
accompanied by ischemic necrosis and cardiovascular col-
lapse. The second syndrome is a more protracted condition
called “severe sepsis”, which refers to an association with
o r g a nd y s f u n c t i o n ,s u c ha sh y p o x e m i a ,o l i g u r i a ,l a c t i ca c i -
dosis, and elevated liver enzymes or altered cerebral function
[3,4].Thislessacutesyndromekillsmoreslowly,progressing
over 7–14 days with a mortality rate of 30–70%. In some
cases, these two syndromes represent two diﬀerent stages
in the progression of sepsis. If patients survive to the acute
episode of septic shock, they may develop a state of severe
sepsis characterized by progressive organ damage in the liver,
kidneys, and lungs [8]. However, thesetwo syndromes are, in
fact, independent disorders, and not all patients with septic
shock develop severe sepsis, and vice-versa.
Despite the recent advances in antibiotics and critical
care, severe sepsis remains a major cause of death, in part
because antibiotics cannot control systemic inﬂammation
a n ds e v e r es e p s i si sn o te x c l u s i v e l yp r o d u c e db yi n f e c t i o n s .
Trauma, ischemia, and severe injury also contribute to the
pathogenesis of the syndrome, which is characterized by
an overwhelming production of inﬂammatory cytokines
including TNF, interleukin (IL)-1, and HMGB1. These
cytokines trigger beneﬁcial inﬂammatory responses to con-
ﬁne the infection and tissue damage. However, the excessive
production of these cytokines can produce inﬂammatory
responses, being even more death-defying than the original
trauma or infection [9–11]. This concept is especially
notable in severe sepsis, where the excessive production
of inﬂammatory cytokines causes capillary leakage, tissue
injury, and lethal multiple organ failure. Early cytokines like
TNF and IL-1 peak within the ﬁrst hours after the infection,
then circulatory levels revert to near baseline by 3-4 hours [9,
11]. This characteristic kinetic of “early” cytokines provides
a narrow therapeutic window for clinical intervention.
“Late” mediators of sepsis are those cytokines that are
producedinthelaterstagesofthepathogenesis.TheHMGB1
is one of the delayed cytokines secreted by macrophages 20
hours after activation with endotoxin. In vivo HMGB1 is
detected in serum beginning 20–72 hours after the onset
of the infection. HMGB1 appears to be necessary and
suﬃcient mediator for the severe sepsis because systemic
HMGB1 is found in patients and experimental animals with
severe sepsis [10]. Administration of recombinant HMGB1
to mice recapitulates the characteristic organ dysfunction
of severe sepsis, including derangement of intestinal barrier
function, acute lung injury, and lethal multiple organ failure
[11–15]. The inhibition of HMGB1 secretion or activity
prevents endotoxin- or bacteremia-induced multiple organ
failure [11]. Neutralizing antibody or “A-box”, a truncated
DNA-binding domain, acts as a competitive inhibitor of
HMGB1. Neutralizing antibody represents a therapeutic
agent which makes HMGB1 an eﬀective target to reverseMediators of Inﬂammation 3
the established sepsis in a clinically relevant time [11]. Ethyl
pyruvate, an anti-oxidant that inhibits HMGB1 secretion
from macrophages, can be added a day after TNF production
to reverse the established sepsis [16, 17].
3.Pathophysiology ofSepsis
The reticuloendothelial system (RES), part of the immune
system, consists of the phagocytes, monocytes, and
macrophages accumulating in lymph nodes and the
spleen. The Kupﬀer cells of the liver and histiocytes are also
part of the RES. RES cells primarily target the pathogens
or toxins in the process of sepsis in the lung, liver, and
spleen. After infection, leukocytes are localized in sinusoids,
perisinusoidal and perivascular spaces of the liver and
lungs. In the spleen, leukocytes are localized in follicles
of the red and white pulps gathering with hematopoietic
cells. Spleen is a critical organ directing the innate immune
responses and modulating inﬂammation. Spleen has two
important immune functions: producing speciﬁc antibodies
and serving as a ﬁlter system for opsonized bacteria in the
blood stream. There are plenty of hematopoietic cells in the
spleen, which are also involved in the inﬂammation. The
growth factors, cytokines, and interferon-gamma all play an
important role in proliferation and diﬀerentiation as well
as apoptosis of these cells. IL-1, IL-6, and TNF released by
a c t i v a t e dm o n o c y t e sa n dm a c r o p h a g e sh a v eb e e nc o n ﬁ r m e d
in vitro and in vivo to induce lymphocyte apoptosis
and activate lymphoid cells [18, 19]. The inﬂammation
associated functional incapacity of macrophages to release
proinﬂammatory cytokines IL-1 and IL-6 inhibits the
activity of caspase 1 and enhances the activities of caspase
3, 8, and 9, which are responsible for the endonuclease
activation causing apoptosis [20].
The innate immune system protects against infection
and tissue injury through the specialized organs of the
RES, including the lungs, liver, and spleen. The central
nervous system regulates innate immune responses via the
vagus nerve; a mechanism termed the cholinergic anti-
inﬂammatory pathway. Vagus nerve stimulation inhibits
cytokine production by signaling through the alpha7nAChR
[6]. Previously, the functional relationship between the
cholinergic anti-inﬂammatory pathway and the RES was
unknown. Now it has been shown that vagus nerve stim-
ulation fails to inhibit TNF production in splenectomized
animals during lethal endotoxemia [21]. Surgical sectioning
of the common celiac nerve abolishes the TNF suppression
by vagus nerve stimulation, suggesting that the cholinergic
pathway is functionally connected to the spleen via this
branch of the vagus nerve. Administration of alpha7nAChR
agonist nicotine can mimic vagus nerve stimulation and
inhibit release of proinﬂammatory cytokines from immu-
nized cells of lymph system including spleen tissue. These
resultsrevealaspeciﬁcandphysiologicalconnectionbetween
the nervous and innate immune systems that may be
exploited through either electrical vagus nerve stimulation
or administration of alpha7nAChR agonists to inhibit proin-
ﬂammatory cytokine production during infection and tissue
injury (Figure 1).
Lung injury and a severe form called acute respiratory
distress syndrome (ARDS) represent a major portion of
mortality in intensive care units in the US [22]. An increase
in HMGB1 levels were seen in plasma and epithelial lining
ﬂuids in lung injury [23]. Intratracheal administration of
recombinant HMGB1 induced a dose-dependent interstitial
and intra-alveolar neutrophil accumulation and lung edema
at 8 and 24 hours postadministration [22]. There were
increased levels of proinﬂammatory cytokines MIP-2, TNF,
and IL-1 [24]. Accordingly, HMGB1 antibodies reduced
this neutrophil accumulation, edema, and lung permeability.
Instillation of endotoxin in mice caused inﬂammatory cell
migration to lungs, destruction of pulmonary parenchyma
cells, pulmonary hemorrhage, and acute lung injury [23].
High levels of HMGB1 were detected in plasma and bronchi-
olar ﬂuid in LPS instilled mice, implicating an involvement
of macrophage cells. Similar acute lung injury was identiﬁed
in a polymicrobial peritonitis model of severe sepsis [24].
Bacteria translocate from the gut to systemic organs, but
the route they take is unclear. Zymosan, which activates the
complements, was used to induce a systemic inﬂammation
in rats. At a lower dose (0.1mg/g) the bacteria translocated
to the mesenteric lymph node complex, whereas at a higher
dose (0.5mg/g) the bacteria translocated systematically via
the portal vein rather than the mesenteric lymph [25]. As
a ﬁrst line of defense, macrophages become activated, and
are speciﬁcally adapted to respond in an attempt to localize
or ward oﬀ the foreign pathogens. Uncontrolled activation
of macrophages and the loss of intestinal barrier function
have been implicated in the development of ARDS and mul-
tiple organ failure. Inﬂuence of drug-induced macrophage
elimination on zymosan-mediated systemic inﬂammatory
responses was tested in a project study [26]. Macrophage-
depleted mice were challenged for 2 days with diﬀerent doses
of zymosan (0.1 to 1.0mg/g). 24 hours after the challenge,
systemic stress was determined and translocation of bacteria
to mesenteric lymph node, liver, spleen, and blood was
measured. The macrophage-depleted mice had signiﬁcant
high-bacterial spreading systemically and low-toxic reaction
of zymosan with the 12-day mortality rates 0% compared
to 27% in the control animals [27]. Therefore, the toxic
responses of animals to zymosan were highly associated
with an excessive activation of macrophages rather than the
systemic spread of bacteria.
Dendritic cells (DCs) that respond to foreign invasion
and function as antigen-presenting to mature B cells to
be speciﬁc antibody producing factories are also involved
in systemic sepsis. Depletion or impaired function of DCs
attributes to the mortality of the sepsis. To study the role
of DC immune in LPS-induced sepsis, a transgenic mouse
model with DCs overexpressing a human form of anti-
apoptotic protein Bcl-2 (DC-hBcl-2 mice) has been used
[28]. The transgenic mice DCs maintain the diﬀerentiation
potential of Th1 cells to enhance T cell activation. Bcl-2-
producing DCs are higher resistance to LPS-induced DC
loss and immunosuppression, and improves animal survival
in LPS-induced shock in DC-hBcl-2 mice. Therefore, DC
death was proven as a key determinant of endotoxin-induced
immunosuppression and mortality in mice.4 Mediators of Inﬂammation
4. Comparison of Experimental
Models of Sepsis
The body may develop the inﬂammatory responses to
microorganisms (or microbes) in the circulatory stream,
urine, skin, or any organ tissues. On the contrary, sys-
temic inﬂammatory response syndrome (SIRS) may occur
in patients without the presence of infection, such as in
those with trauma, burns, hemorrhage, or some nonspeciﬁc
inﬂammatory diseases like chemical pneumonitis, pancre-
atitis, and so forth [29]. Sepsis may become severe when
inﬂammatory response leads to organ dysfunction due to
hypotension or septic shock. The organ dysfunction may
occur in one or more organs, which is called multiple organ
dysfunction syndrome [30]. From cell signaling pathway and
molecular biological perspective [31], the balance between
the pro- and anti-inﬂammatory cytokines is disturbed in
SIRS.Inaddition tooverproductionofTNF, IL-1,IL-2,IL-6,
andIL-12,otherinﬂammatorymediatorssuchasC5ainvolve
the complement cascade. The complement cascade associ-
ated mediators unbalance between the coagulation and ﬁbri-
nolysis systems, and between the adrenergic and cholinergic
pathways. The overwhelmed clotting system and neuron
transmitters contribute to an immunosuppression or anergy.
In order to study, this multitude of activity, which may
eventually lead to beneﬁcial clinical advance, experimental
animal model systems which attempt to emulate systemic
sepsis are devised. The most common are discussed below.
Endotoxemia refers to the presence of endotoxins in
the blood. Endotoxemia emulates sepsis by intravenous
administration of endotoxin lipopolysaccharide (LPS), a cell
membrane component of Gram negative bacteria. Rodent
models are the most common representatives, but they have
small blood volume and are relatively resistant to endotoxin.
A large dose of endotoxin results in sudden cardiovascular
collapse and death [32]. Baboons more closely resemble
human being in endotoxin sepsis with typical coagulopathy
and progressive multiorgan dysfunctions [33]. The insult
of LPS presumes that it is the host response, rather than
intact pathogen that causes the clinical features of sepsis. LPS
sepsis increases proinﬂammatory cytokines in serum with
septic clinical manifestations, which are closely mimicked
with administration of recombinant TNF or IL-1 to the
animals [8, 34]. Mice injected with LPS peaked the cytokines
at 3 hours and started to decline at 8 hours, whereas in the
cecumligationandpuncture(CLP)model(describedbelow)
the cytokines had higher level at 8 hours and continued to
increase thereafter. Although mortality rates were similar in
both LPS and CLP models, the signiﬁcant diﬀerences in the
kinetics and magnitude of cytokine production suggested
that the CLP model more accurately had the cytokine proﬁle
of sepsis.
Sublethal and lethal doses of endotoxin or living E.
coli in nonhuman primates resulted in a severe dissemi-
nated intravascular coagulation [35]. The inﬂammatory and
hemostatic responses involved the microvascular endothe-
lium and regulatory anticoagulant networks, which con-
tributed to multiorgan dysfunction. Pretreatment with a
TNF inhibitor had hemodynamic improvement and better
survival in baboons, who otherwise exhibited an exaggerated
TNF response with cardiovascular collapse and early death
from a LD100 dose of E. coli [32]. Anti-TNF or its soluble
receptor is protective in LPS animal models but doest not
improve survival in clinical trials for most patients. LPS may
be a good model for endotoxic shock, and can demonstrate
some featuressuch as earlyproduction of cytokines, butdoes
not adequately resemble the pathophysiology typically to the
evolving multiorgan dysfunction presented in the sepsis.
CLP is another experimental model of sepsis to emulate
human sepsis, but a more natural replica of peritonitis. Here
the cecum is perforated, ligated, and the natural contents
of the colon are leaked into the peritoneum, causing
polymicrobial infection. The leakage sequentially results in
bacteremia, sepsis, septic shock, SIRS, and eventual death.
The cytokine proﬁle is diﬀerent from that of LPS infusion. In
LPS, early and high transitory levels of IL-1, TNF, IL-6, and
hypothermia or other clinical symptoms appear within a few
hours. In CLP the levels of these proinﬂammatory cytokines
and mortality go up proportionately to the length of ligated
cecum [36]. IL-1, IL-6, and C5a reach moderately high level
at 12–24 hours; and serum levels of LPS are minimum or
even undetectable at this time similar to that in human
sepsis. At this time point, anti-C5a or anti-IL-6 rather than
anti-LPS or anti-TNF is more protective to the animals
[37–39]. Although consistency of surgical procedures is a
factor, CLP is currently a typical standard in experimental
models of sepsis.
5. Systemic Inﬂammation in Hemorrhage
Severe hemorrhage is a common cause of morbidity and
mortality in critical care medicine [40–42]. Hypovolemia
and hypotension that limit the oxygen consumption and
cause oxidative stress and organ injury determine the
prognosis. After losing over ∼50% of the total blood volume,
the system becomes unable to reestablish tissue perfusion,
causing lethal cardiovascular shock and multiple organ
failure. During severe hemorrhageand ﬂuid resuscitation, an
overwhelming production of inﬂammatory cytokines such
as TNF and HMGB1, and signs of SIRS, is usually present.
Practically, the conventional resuscitation ﬂuid is ﬁrst used
to reperfuse the tissues. However, this is unable to prevent
inﬂammatory responses and the SIRS [41–43].
Hemorrhagic shock is conceived as a global ischemic
insult to frequently cause SIRS with tissue damage and
multiple-organ dysfunctions [44], which involves a complex
mechanism in pathogenesis. The most widely recognized
ways appear to be associated with ischemia, reperfusion,
and stimulation of cells of the innate immune system.
Ischemia and reperfusion is known to result in oxidative;
and SIRS is found to be obvious during or postischemic
resuscitation [45, 46]. The extent of tissue ischemia, that
deﬁnes the degree of oxygen debt, correlates with a systemic
inﬂammatory response that renders the injured patient at
risk of postresuscitation multiple organ dysfunctions [47].
Regarding the duration of hemorrhagic shock it has been
shown that the longer the shock persists the more intense
is the inﬂammatory response that follows [48]. Similarly,Mediators of Inﬂammation 5
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Figure 2: Inﬂammatory response of HMGB1 and its attenuation by ethyl pyruvate. HMGB1 is liberated from macrophages into the
extracellular milieu following cell membrane perturbations during sepses, hemorrhage, and injury. HMGB1-mediated nitric oxide (NO)
leakages the endothelial line leading to a high permeability. NFKB signally stimulated by HMGB1 in macrophage regulates the release of
TNF cytokine and interleukins. Inﬂammatory shock and animal death result due to vascular collapse and cytokine toxicity of the organ
tissues. By attenuating the HMGB1 pathways with hextend-ethyl pyruvate (HEP), animals may improve survival with the dependent dosage.
survival seems to be improved with early resuscitation, and
mortality to be high with delayed resuscitation [49]. It has
been shown that the severity of shock is a more important
determinant than the duration of shock in generating a
higher mesenteric lymph ﬂow at the postshock period. Like-
wise,thislymphengendersgreaterbioactivityasmeasuredby
human polymorphonuclears (PMN) priming for respiratory
burst [50].
TNF is considered as pivotal inﬂammatory agent in
hemorrhage. TNF diﬀuses in the bloodstream and initiates
a fatal cardiovascular collapse [43]. TNF is a suﬃcient
and necessary mediator of hemorrhagic shock, because
(i) it is detected to be rich in patients and experimental
models of hemorrhagic shock; (ii) it may contribute to
the lethality of hemorrhagic shock; (iii) its neutralization
attenuatescardiovascularshock.TNFplaysanimportantrole
in excessive autodestructive inﬂammation and may ﬁnally
induce multiple organ failure through the activation of
neutrophils [51]. TNF is known to trigger the release of
other proinﬂammatory cytokines, such as IL-1b and IL-6
[52]. In addition, TNF has much more potency than that
of other cytokines in activation of neutrophils [53]. Many
experimental studies have focused on the production of TNF
inseverehemorrhage(lossof50%ofthetotalbloodvolume)
or prolonged hemorrhage with ﬂuid resuscitation. Recently,
it has been shown that ethyl pyruvate can inhibit TNF
production from human and murine macrophages [16, 17].
Invivo,ethylpyruvateattenuatedsystemicinﬂammationand
improved survival in experimental models of hemorrhage
[54–56].
InadditiontoTNF,recentstudiesindicatedthatHMGB1
also plays an important role in hemorrhagic shock. HMGB1
was originally identiﬁed as a nuclear DNA-binding protein
that functions as a structural cofactor. However, during
cellular damage or necrosis, HMGB1 is liberated into the
extracellular milieu where it functions as an inﬂammatory
cytokine [57–59]. Extracellular HMGB1 sustains inﬂamma-
tory responses producing abrupt cardiac standstill, intestinal
derangement and acute lung injury [9, 60–62]. For these
reasons, there is a major interest in inhibiting the production
of these factors during resuscitation (Figure 2).
6. Comparison of Experimental
Models of Hemorrhage
Hemorrhage is frequently associated with trauma. The
immune response to hemorrhage would be expected to
be diﬀerent in conscious versus unconscious individuals;6 Mediators of Inﬂammation
and anesthesia and analgesics have diﬀerent immune con-
sequences; hence the diﬀerent physiological and immune
responses may occur and diﬀerent treatment regimens may
need to be applied. For example, Phenobarbital increases
extra-alveolarpermeabilityandpromotesneutrophilrecruit-
ment in the lungs [63]. Morphine induces immunosuppres-
sive eﬀects mediated by the induction of corticosterone [64].
Manyanimalmodelshavebeenusedfortrauma/hemorrhage
research [65]. For these reasons, we studied hemorrhage and
resuscitation in experimental rat models of conscious (with-
out anesthesia), anesthetized, and anesthetized plus trauma.
Rat hemorrhage was normalized by constant pressure rather
than constant volume in order to directly compare the 3
conditions. Rats were bled to a mean arterial pressure (MAP)
of 35–40mmHg. Many diﬀerent bleeding protocols have
been used to emulate real life conditions [51]; and a recent
study claimed to emulate true conditions by varying rate
of blood loss that maximized physiologic insult [66]. In
our studies, the conscious rats took more shed blood, and
the anesthetized ones with trauma took less blood than
the traditional anesthetized model to achieve the similar
MAP result. Diﬀerences in shed blood did not correlate
with survival. The nonresuscitated rats of anesthetized and
anesthetized plus trauma had a similar average survival time
of 160 and 167 minutes, respectively, whereas the conscious
rats had a statistically signiﬁcant shorter average survival
time of 87 minutes in spite of their ability to vasoconstrict
and compensate blood loss, which was neutralized by the
constant pressure regimen [67].
Advanced resuscitation ﬂuid, Hextend, a novel plasma
volume expander containing 6% hydroxyethyl starch in
Ringer’s lactate was used for resuscitation, which signif-
icantly improved survival in all models [67]. Hetastarch
creates oncotic pressure, which is normally provided by
blood proteins and permits retention of intravascular ﬂuid.
AlthoughHextendprotectedtheanimalsofanesthetizedplus
trauma the most in survival rate, 40% (P>. 01 versus
nonresuscitated) as compared to 25% for conscious and
10% for the anesthetized only, it failed to increase the
average survival time (delay of death after hemorrhage) in
animalswithanesthesiaandtraumaascomparedtotheother
two models. All nonsurvival animals died within 7 hours
of hemorrhage, and all others survived for 5 day follow-
up period. Blood chemistries were measured at 2 hours
after hemorrhage, which was the average time of death for
nonresuscitated conscious animals. All models had similar
uremia, which was not corrected and prevented by Hextend
resuscitation. All models had acidosis (increased Anion Gap)
with conscious model being signiﬁcantly higher than the
others; however, Hextend resuscitation signiﬁcantly restored
AnGap back to normal level in conscious model. All models
had hyperglycemia. Serum TNF levels measured (by ELISA)
at that time demonstrated 2-fold signiﬁcantly higher (P<
.05) in rats of conscious and anesthetized plus trauma than
animals with anesthesia. TNF levels measured in buﬀer-
washed heart also had parallel 2-fold signiﬁcant increase
(P<. 01)inanesthetizedplustraumaandconsciousratsover
anesthetized animals. All washed organs taken for analyses
had TNF values 3 orders of magnitude higher than serum
levels, (i.e., organs/serum = μg/pg) expressed by protein-
standardized amounts. The lung and liver had signiﬁcantly
higher TNF levels in all models with the highest in conscious
rats. The spleen showed similar results in anesthetized plus
trauma model, but was not as clear for the others [67].
7. Pathophysiology of Hemorrhage
It is speculated that the spleen is a major source of systemic
TNF content in hemorrhage. Inhibition of TNF production
in the spleen prevents cardiovascular shock [6, 68]. In a
rat model of nonlethal hemorrhagic shock, TNF carried in
the lymph or portal vein would promote the endothelial
cell damage and activate the neutrophils to a greater extent
[69]. The samples were collected from eﬀerent lymph duct
draining the mesenteric lymph node complex 6 hours after
sublethal hemorrhagic shock. As well, the portal vein plasma
was collected, and both samples were tested for endothelial
cell (HUVEC) monolayer permeability. The lymph but not
portal vein plasma from postshock was showed to increase
the HUVEC permeability and to be cytotoxic to endothelial
cells. Postshock lymph induced a greater formation in neu-
trophilsuperoxideanddeterioratedtheneutrophil-mediated
endothelial cell damage during incubation.
Since the lung is the ﬁrst organ coming in contact with
mesenteric lymph, its injury due to hemorrhagic shock
m i g h tb ec a u s e db yf a c t o r sp r e s e n ti nm e s e n t e r i cl y m p ha s
compared to the portal vein plasma. An outbreak of lung
dysfunction may be directly related to the release of TNF
and IL-1 beta during acute hemorrhage [70]. Except for
spleen and lymph system, heart is also shown to play an
important role in the expression of TNF and IL-1 [71–
73]. These cytokines diminish cardiac contraction by direct
parenchymal damage with calcium handling disruption [72,
74]. In addition, they are important mediators of induction
of leukocyte chemotaxis in conjunction with adhesion
molecules such as beta-4 integrin, intercellular adhesion
molecule 1, and neutrophils. An outbreak of fatal heart
dysfunction or failure caused by hemorrhagic shock was
reported [70, 75, 76]. The p38 mitogen-activated protein
kinase (p38 MAPK) is activated in the cardiac ischemic
state [77–79], which promotes cellular stress responses
such as proliferation, diﬀerentiation, and production of the
proinﬂammatory cytokines [77, 80, 81]. Several investigators
demonstrated that p38 MAPK in the cardiac ischemic state
was activated not only in macrophage or endothelial cells
but also in cardiac myocytes [77, 81], and that the activation
occurred immediately after the ischemic induction [15]. The
beta-2 integrin and vascular-cell adhesion molecule 1, may
involved in activation [82–84]. The adhered neutrophils are
known to generate and release numerous active substances
such as proteolytic enzymes and reactive oxygen species.
All of them have the potential to damage the endothelial
layer and adjacent tissue [70, 80, 85]. The activation of
p38 MAPK caused myocardial apoptosis, resulting in cardiac
dysfunction within a short time after myocardial infarction
[86].Mediators of Inﬂammation 7
8. Comparison of Systemic Inﬂammation
in Sepsis and Hemorrhage
The balance of pro- and anti-inﬂammatory mediators
derived from the innate immune system deﬁnes the progres-
sion and severity of sepsis and hemorrhage. An overproduc-
tion of endogenous proinﬂammatory mediators, including
cytokines, platelet-activating factor, oxygen radicals, and
nitric oxide, synergistically interact to mediate hypotension,
multiple organ failure, and death. Progression from sepsis
to septic shock coincides with the increase in circulating
levels of proinﬂammatory cytokines such as TNF, interferon
gamma, IL-1, and IL-6 [87]. Studies from animal models
suggest that inhibition of these early mediators suppresses
particular facets of the pathological response. For instance,
neutralizing antibodies to TNF, the ﬁrst cytokine elaborated
in the septic inﬂammatory cascade, prevent death when
administered before or concurrent with lethal doses of
live Escherichia coli [9]. TNF is a necessary and suﬃcient
mediator of septic shock in experimental animal models.
First, TNF is produced in animals during septic shock.
Second, removing TNF from diseased animals, by either
pharmacological strategies or genetic disruption, signiﬁ-
cantly improves survival after endotoxin challenge. Last,
administration of TNF to normal animals reproduces the
pathological sequelae of septic shock [9, 88, 89]. The
identiﬁcation of TNF as an essential mediator of Gram-
negative septic shock focused attention on the development
of therapies directed at endogenous toxins. A number of
other proinﬂammatory cytokines have since been implicated
in the mediation of endotoxin lethality. For instance, IL-
1[ 90, 91], leukemia inhibitory factor (LIF) [92, 93], IFN
gamma, and migration inhibitory factor (MIF) may each
contribute to the pathogenesis of endotoxemia or septic
shock. Clearly, the pathogenesis of sepsis is modulated by an
interactionbetweentheseandperhapsothermediators.Each
of these secondary mediators can be induced by TNF.
The early systemic release of TNF during endotoxemia
activates lethal downstream pathological responses [91].
Endotoxin also initiates anti-inﬂammatory mechanisms that
down regulate or suppress potentially injurious proin-
ﬂammatory mediators. In LPS-stimulated monocytes, for
example, the local accumulation of prostaglandin E2 (PGE2)
inhibits the synthesis of proinﬂammatory cytokines that can
restrain an acute cytokine response [94]. Anti-inﬂammatory
cytokines (e.g., IL-10 and transforming growth factor beta
[TGF-beta]) are involved in the downregulation of the
inﬂammatory response. For instance, IL-10 can deactivate
macrophages; and the TNF levels in patients with trauma
get higher when IL-10 levels are depressed, a scenario that
has been implicated in the onset of septic complications
[95]. TGF beta is a potent inhibitor of monocyte activation
[96]; and signiﬁcantly elevated levels of TGF beta have been
observed in monocytes derived from immunosuppressed
patients after trauma. New evidence suggests that the central
nervous system can directly, and rapidly, attenuate the
TNF response to endotoxin through eﬀerent vagus nerve
signals to tissue-resident macrophages [97]. This eﬀect is
mediated by acetylcholine, the principal neurotransmitter
of the vagus nerve, which signals via nicotinic cholinergic
receptors present on macrophages [98]. Thus, the complex
cytokine milieu in septic patients is characterized by the
interactionbetweenanti-inﬂammatoryresponsesandpoten-
tially injurious proinﬂammatory responses that are tightly
regulated by neural and humoral pathways.
Hemorrhagic shock is a severe life-threatening emer-
gency aﬀecting all organ systems of the body by depriving
tissue of suﬃcient oxygen and nutrients owning to decreased
cardiac output. Moreover, resuscitation can trigger systemic
inﬂammatory responses that can be more dangerous than
the initial hemorrhage. Conventional resuscitation ﬂuids are
designed to restore circulatory volume and tissue perfusion,
but they failed to prevent inﬂammatory responses. An
acute loss of blood results in a cascade of compensatory
events that aﬀect all organ systems. The initial response to
hypovolemia is to decrease circulation to less vital organs
such as the kidneys, gut, and skin in order to preserve
circulation to priority organs such as the heart, brain, lungs,
and skeletal muscle. This shunting to vital organs is triggered
from a decrease in cardiac output and subsequently pulse
pressure, which is sensed by baroreceptors within the aortic
arch and atrium. Neural reﬂexes then cause a sympathetic
outﬂow to the heart and other organs, which respond by
increasing heart rate and vasoconstriction. A hormonal
response occurs, and activation of the renin system leads
to vasoconstriction and the retention of sodium and water.
The anterior pituitary and adrenal medulla are stimulated
to release adrenocorticotropic hormone, epinephrine, and
norepinephrine, which enhance compensatory mechanisms.
At the cellular level, a decrease in perfusion causes the cells to
switch from aerobic to anaerobic metabolism. Lactic acid is
formed and that causes metabolic acidosis. If the blood loss
continues, the compensatory mechanisms begin to fail and
damage occurs throughout the body [99, 100].
9. Summary
Bothsepsisandhemorrhagecandeveloplethalinﬂammatory
responses or systemic inﬂammatory response syndrome
(SIRS). Sepsis can represent an extrinsic activation in
response to infection or bacterial endotoxins. Hemorrhage
can activate similar responses though an intrinsic response
to tissue damage. In both cases, overwhelming inﬂammatory
responses can become more dangerous than the original
pathogenic insult. In this case, eﬃcient anti-inﬂammatory
strategiescanprovidetherapeuticbeneﬁtsforbothsepticand
hemorrhagic clinical settings.
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